Abbott Laboratories vs Hershey Co — how do they compare? Abbott Laboratories trades at $111.14 (market cap $187.95B), while Hershey Co trades at $183.83 (market cap $36.56B). The key difference: Abbott Laboratories is far larger — about 5.1× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| ABT | HSY | |
|---|---|---|
Market Cap | $187.95B | $36.56B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $236.28 |
52-Week Low | $82.57 | $162.31 |
Enterprise Value | $214.96B | $41.70B |
Dividend Yield | 2.32% | 3.19% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Hershey (HSY) trades at $183.19, up 0.24% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates by 33% and revenue growth of 4.5-5% guidance. Recent earnings show significant margin recovery to 45.3% as cocoa prices decline, supporting the stock's premium valuation at 24.86 P/E. Analyst consensus price target of $196.78 suggests 7.4% upside potential from current levels.
HSY presents a compelling investment case with improving fundamentals, dividend growth resumption, and margin expansion. However, risks include volume declines in salty snacks, competitive pressures, and potential cocoa price volatility. The stock's current technical overbought condition near resistance at $184 warrants caution despite positive earnings momentum and institutional support.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →